Of those 37, seven were previously suggested as candidate biomarkers and/or therapeutic targets (MMP-1/2/3, TNFR1/2, IL-22, Osteopontin) (16–24) in HAM, while most of them were not previously interrogated at the protein level in HAM patients but have been demonstrated in other neuroinflammatory or neurodegenerative disorders, such as CHI3L1 (also known as YKL-40) in HIV-Associated Neurocognitive Decline (HAND) (25). Here, IL22 is linked to tropical spastic paraparesis.